

Title (en)
ADIPONECTIN PRODUCTION ENHANCER

Title (de)
MITTEL ZUR VERSTÄRKUNG DER ADIPONECTIN-PRODUKTION

Title (fr)
ACTIVATEUR DE LA PRODUCTION D'ADIPONECTINE

Publication
EP 1621210 A4 20090805 (EN)

Application
EP 04729769 A 20040427

Priority
• JP 2004006100 W 20040427
• JP 2003123768 A 20030428
• JP 2004012265 A 20040120

Abstract (en)
[origin: EP1621210A1] The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.

IPC 8 full level
A61K 31/00 (2006.01); **A61K 31/22** (2006.01); **A61K 31/366** (2006.01); **A61K 31/40** (2006.01); **A61K 31/404** (2006.01); **A61K 31/4418** (2006.01); **A61K 31/47** (2006.01); **A61K 31/505** (2006.01); **A61K 45/00** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01)

CPC (source: EP US)
A61K 31/00 (2013.01 - EP US); **A61K 31/047** (2013.01 - EP US); **A61K 31/10** (2013.01 - EP US); **A61K 31/191** (2013.01 - EP US); **A61K 31/21** (2013.01 - EP US); **A61K 31/22** (2013.01 - EP US); **A61K 31/366** (2013.01 - EP US); **A61K 31/40** (2013.01 - EP US); **A61K 31/404** (2013.01 - EP US); **A61K 31/4418** (2013.01 - EP US); **A61K 31/47** (2013.01 - EP US); **A61K 31/495** (2013.01 - EP US); **A61K 31/505** (2013.01 - EP US); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP)

Citation (search report)
• [X] EP 0956867 A1 19991117 - LIEBEL FRANZ PETER DR [DE]
• [X] US 5298497 A 19940329 - TSCHOLLAR WERNER [US], et al
• [X] WO 9513063 A1 19950518 - MERCK & CO INC [US], et al
• [E] WO 2004052368 A1 20040624 - ENDOCRINE HEALTH I GOETEBORG A [SE], et al
• [X] EP 0671170 A1 19950913 - BRISTOL MYERS SQUIBB CO [US]
• [PX] EP 1325745 A1 20030709 - NISSAN CHEMICAL IND LTD [JP], et al
• [X] WO 0045818 A1 20000810 - ASTRAZENECA UK LTD [GB], et al
• [X] US 5130333 A 19920714 - PAN HENRY Y [US], et al
• [PX] HUNNINGHAKE DONALD B ET AL: "Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.", CLINICAL THERAPEUTICS, vol. 25, no. 6, June 2003 (2003-06-01), pages 1670 - 1686, XP002533400, ISSN: 0149-2918
• [PX] DEEDWANIA PRAKASH ET AL: "Comparative effects of statins on atherogenic dyslipidemia in patients with the metabolic syndrome.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 43, no. 5 Supplement A, 3 March 2004 (2004-03-03), & 53RD ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY; NEW ORLEANS, LA, USA; MARCH 07-10, 2004, pages 485A, XP009118570, ISSN: 0735-1097
• [PX] NEWMAN C ET AL: "Efficacy of atorvastatin in dyslipidemic patients with metabolic syndrome in the ACCESS study.", DIABETES, vol. 52, no. Supplement 1, 2003, & 63RD SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION; NEW ORLEANS, LA, USA; JUNE 13-17, 2003, pages A494, XP009118584, ISSN: 0012-1797
• [XY] BALLANTYNE CHRISTIE M ET AL: "Efficacy of rosvastatin 10 mg in patients with the metabolic syndrome.", THE AMERICAN JOURNAL OF CARDIOLOGY 6 MAR 2003, vol. 91, no. 5A, 6 March 2003 (2003-03-06), pages 25C - 27C ; dis, XP002533401, ISSN: 0002-9149
• [XY] OLSSON ANDERS G ET AL: "Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor.", CARDIOVASCULAR DRUG REVIEWS, vol. 20, no. 4, January 2002 (2002-01-01), pages 303 - 328, XP002533402, ISSN: 0897-5957
• [XY] FREEMAN D J ET AL: "Prevastatin and the development of diabetes mellitus; evidence for a protective treatment effect in the West of Scotland coronary prevention study", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 103, no. 3, 23 January 2001 (2001-01-23), pages 357 - 362, XP002984071, ISSN: 0009-7322
• [XY] SUGIMOTO T ET AL: "PRAVASTATIN VERSUS SIMVASTATIN IN HYPERLIPIDEMIC PATIENTS WITH TYPE 2 DIABETES MELLITUS", CURRENT THERAPEUTIC RESEARCH, XX, XX, vol. 60, no. 7, 1 July 1999 (1999-07-01), pages 404 - 413, XP001070347
• [DA] WEYER C ET AL: "HYPOADIPONECTINEMIA IN OBESITY AND TYPE 2 DIABETES: CLOSE ASSOCIATION WITH INSULIN RESISTANCE AND HYPERINSULINEMIA", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, ENDOCRINE SOCIETY, CHEVY CHASE, MD, vol. 86, no. 5, 1 May 2001 (2001-05-01), pages 1930 - 1935, XP001119512, ISSN: 0021-972X
• See references of WO 2004096278A1

Cited by
EP2051725A4; US9746463B2

Designated contracting state (EPC)
DE ES FR GB IT

DOCDB simple family (publication)
EP 1621210 A1 20060201; **EP 1621210 A4 20090805**; **EP 1621210 B1 20130619**; AU 2004233693 A1 20041111; AU 2004233693 B2 20070719; CA 2524134 A1 20041111; CA 2524134 C 20170704; ES 2421520 T3 20130903; US 2007059357 A1 20070315; US 9345671 B2 20160524; WO 2004096278 A1 20041111

DOCDB simple family (application)
EP 04729769 A 20040427; AU 2004233693 A 20040427; CA 2524134 A 20040427; ES 04729769 T 20040427; JP 2004006100 W 20040427; US 55507604 A 20040427